(Q26830362)

Alan P. Venook

series ordinal

2

1 reference

language of work or name

1 reference

June 2011

1 reference

Clinical Colorectal Cancer

published in

1 reference

volume

10

1 reference

issue

2

1 reference

page(s)

73-80

1 reference

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Ubiquitous somatic mutations in simple repeated sequences reveal a new mechanism for colonic carcinogenesis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A gene-expression signature as a predictor of survival in breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Gene expression profiling predicts clinical outcome of breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A systematic review and meta-analysis of the relationship between chromosome 18q genotype, DCC status and colorectal cancer prognosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Systematic review of microsatellite instability and colorectal cancer prognosis

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Molecular predictors of survival after adjuvant chemotherapy for colon cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

7 April 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Gene expression profiles as predictors of poor outcomes in stage II colorectal cancer: A systematic review and meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Genetic prognostic and predictive markers in colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Microsatellite instability predicts improved response to adjuvant therapy with irinotecan, fluorouracil, and leucovorin in stage III colon cancer: Cancer and Leukemia Group B Protocol 89803.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Microsatellite instability in colorectal cancer and association with thymidylate synthase and dihydropyrimidine dehydrogenase expression

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Development of a clinically feasible molecular assay to predict recurrence of stage II colon cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

The role of molecular markers in predicting response to therapy in patients with colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Association between chromosomal instability and prognosis in colorectal cancer: a meta-analysis

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A prospective randomised phase III trial of adjuvant chemotherapy with 5-fluorouracil and leucovorin in patients with stage II colon cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Gene expression signature in advanced colorectal cancer patients select drugs and response for the use of leucovorin, fluorouracil, and irinotecan

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Molecular staging for survival prediction of colorectal cancer patients

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Systemic therapy for colorectal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Should Dukes' B patients receive adjuvant therapy? A statistical perspective

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial.

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Gene expression signature for recurrence in stage III colorectal cancers.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Molecular signature for lymphatic metastasis in colorectal carcinomas

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Analysis of gene expression profiles reveals novel correlations with the clinical course of colorectal cancer

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Gene expression profiling of colorectal cancer and metastases divides tumours according to their clinicopathological stage.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3561586

BRAFMutation in Metastatic Colorectal Cancer

28 November 2018

1 reference

12 December 2020

Hereditary colorectal cancer

1 reference

12 December 2020

Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer

1 reference

12 December 2020

Prognostic indicators of colon tumors. The Gastrointestinal Tumor Study Group experience

1 reference

12 December 2020

Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic

1 reference

12 December 2020

Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma

1 reference

12 December 2020

Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer

1 reference

12 December 2020

Microsatellite instability and 8p allelic imbalance in stage B2 and C colorectal cancers

1 reference

12 December 2020

Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer

1 reference

12 December 2020

Adjuvant chemotherapy for colon cancer: a confusing area!

1 reference

12 December 2020

Immunohistochemical Test for MLH1 and MSH2 Expression Predicts Clinical Outcome in Stage II and III Colorectal Cancer Patients

1 reference

12 December 2020

Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer

1 reference

12 December 2020

Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients

1 reference

12 December 2020

Stage II colon cancer prognosis prediction by tumor gene expression profiling

1 reference

12 December 2020

Microsatellite instability accounts for tumor site-related differences in clinicopathologic variables and prognosis in human colon cancers

1 reference

12 December 2020

Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study

1 reference

12 December 2020

Adjuvant treatment of colorectal cancer

1 reference

12 December 2020

Distinction of hereditary nonpolyposis colorectal cancer and sporadic microsatellite-unstable colorectal cancer through quantification of MLH1 methylation by real-time PCR

1 reference

12 December 2020

Molecular biology for stage II colorectal cancer: the jury is still out

1 reference

12 December 2020

Hospital lymph node examination rates and survival after resection for colon cancer

1 reference

12 December 2020

Impact of tumor location on nodal evaluation for colon cancer

1 reference

12 December 2020

Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy

1 reference

12 December 2020

Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CLCC.2011.03.001

7 January 2021

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.CLCC.2011.03.001

7 January 2021

Moyamoya disease and moyamoya syndrome

1 reference

https://api.crossref.org/works/10.1016%2FJ.CLCC.2011.03.001

7 January 2021

Gene Expression Signature to Improve Prognosis Prediction of Stage II and III Colorectal Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.CLCC.2011.03.001

7 January 2021

Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.CLCC.2011.03.001

7 January 2021